Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00957996 · ClinicalTrials.gov registry record · Phase 3
Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza
A Phase 3 study, sponsored by BioCryst Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 234
- Enrollment target
NCT00957996: Completed Phase 3 study, sponsored by BioCryst Pharmaceuticals.
NCT00957996 is a Phase 3 study that has completed, run by BioCryst Pharmaceuticals. The registered enrollment target is 234 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00957996, a Phase 3 study, has completed, sponsored by BioCryst Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 234 participants
- Enrollment target
Study Summary
This is a Phase 3, open-label, randomized study of the antiviral activity, safety, and tolerability of intravenous Peramivir in hospitalized subjects with confirmed or suspected influenza infection.
Primary Outcome
The time-weighted change from baseline in log10 tissue culture infective dose50 (TCID50/mL) was calculated on a by-subject basis through 48 hours using the trapezoidal rule with all available data minus the baseline value. Ninety-five percent confidence intervals about the median time-weighted change from baseline were presented for each treatment group.
Interventions
- DRUG Peramivir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 234 participants |
| Start Date | 2009-10 |
| Est. Completion | 2011-08 |
| Phase | Phase 3 |
What the finished NCT00957996 record still lists
NCT00957996 is an interventional study that assigns participants to a tested intervention. The registered 234 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (70% lower).
The record links to 0 conditions, and to 1 intervention - of which Peramivir is the first listed.
NCT00957996 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00957996 about?
NCT00957996 is a clinical study titled "Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza". This is a Phase 3, open-label, randomized study of the antiviral activity, safety, and tolerability of intravenous Peramivir in hospitalized subjects with confirmed or suspected influenza infection.
What is the current status of trial NCT00957996?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 234 participants. The study started on 2009-10. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00957996?
The interventions under investigation include: Peramivir (DRUG).
Who is sponsoring clinical trial NCT00957996?
This trial is sponsored by BioCryst Pharmaceuticals, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00957996's enrollment target sits among peer trials
234 1297th of 2000 higher than 703 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04942717 · 234 participants · NA
Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values
- NCT05208671 · 234 participants · NA
Nutrition to Optimize, Understand, and Restore Insulin Sensitivity in HIV for Oklahoma
- NCT05444465 · 234 participants · NA
Use of the REGENETEN™ Bioinductive Implant System in High Grade Partial-thickness Tears
- NCT05720338 · 234 participants · Phase 3
Is Intraperitoneal Drainage Necessary Following Distal Pancreatectomy?
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia